{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:31:03Z","timestamp":1791304263712,"version":"4.3.1"},"reference-count":86,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,9,14]],"date-time":"2017-09-14T00:00:00Z","timestamp":1505347200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.ymgme.2017.09.004","type":"journal-article","created":{"date-parts":[[2017,9,13]],"date-time":"2017-09-13T15:31:28Z","timestamp":1505316688000},"page":"19-27","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":208,"title":["Contribution of inflammatory pathways to Fabry disease pathogenesis"],"prefix":"10.1016","volume":"122","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8138-3087","authenticated-orcid":false,"given":"Paula","family":"Rozenfeld","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8420-8447","authenticated-orcid":false,"given":"Sandro","family":"Feriozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2017.09.004_bb0005","series-title":"Fabry Disease: Perspectives From 5 Years of FOS","article-title":"Epidemiology of lysosomal storage diseases: an overview","author":"Fuller","year":"2006"},{"key":"10.1016\/j.ymgme.2017.09.004_bb0010","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/nrm3565","article-title":"Signals from the lysosome: a control centre for cellular clearance and energy metabolism","volume":"14","author":"Settembre","year":"2013","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ymgme.2017.09.004_bb0015","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1146\/annurev-physiol-021014-071649","article-title":"Lysosomal physiology","volume":"77","author":"Xu","year":"2015","journal-title":"Annu. Rev. Physiol."},{"key":"10.1016\/j.ymgme.2017.09.004_bb0020","doi-asserted-by":"crossref","first-page":"20423","DOI":"10.1074\/jbc.R110.134452","article-title":"Common and uncommon pathogenic cascades in lysosomal storage diseases","volume":"285","author":"Vitner","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgme.2017.09.004_bb0025","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/jmcb\/mjt022","article-title":"The lysosome: from waste bag to potential therapeutic target","volume":"5","author":"Appelqvist","year":"2013","journal-title":"J. Mol. Cell Biol."},{"key":"10.1016\/j.ymgme.2017.09.004_bb0030","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.0105-2896.2005.00310.x","article-title":"The lysosomal cysteine proteases in MHC class II antigen presentation","volume":"207","author":"Hsing","year":"2005","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.ymgme.2017.09.004_bb0035","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s00109-005-0014-4","article-title":"Autophagy in innate and adaptive immunity against intracellular pathogens","volume":"84","author":"Schmid","year":"2006","journal-title":"J. Mol. Med. (Berl.)"},{"issue":"Suppl. 2","key":"10.1016\/j.ymgme.2017.09.004_bb0040","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1038\/sj.cdd.4401727","article-title":"Immune surveillance of intracellular pathogens via autophagy","volume":"12","author":"Schmid","year":"2005","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.ymgme.2017.09.004_bb0045","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1615\/CritRevImmunol.v26.i3.40","article-title":"T-cell receptor signaling events triggering granule exocytosis","volume":"26","author":"Radoja","year":"2006","journal-title":"Crit. Rev. Immunol."},{"key":"10.1016\/j.ymgme.2017.09.004_bb0050","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00401-007-0296-4","article-title":"Immune system irregularities in lysosomal storage disorders","volume":"115","author":"Castaneda","year":"2008","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.ymgme.2017.09.004_bb0055","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/nrm732","article-title":"Secretory lysosomes","volume":"3","author":"Blott","year":"2002","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ymgme.2017.09.004_bb0060","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10545-008-1040-5","article-title":"Pathogenic cascades in lysosomal disease-Why so complex?","volume":"32","author":"Walkley","year":"2009","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2017.09.004_bb0065","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1083\/jcb.201208152","article-title":"The cell biology of disease: lysosomal storage disorders: the cellular impact of lysosomal dysfunction","volume":"199","author":"Platt","year":"2012","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.ymgme.2017.09.004_bb0070","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1172\/JCI34431","article-title":"A calculated response: control of inflammation by the innate immune system","volume":"118","author":"Barton","year":"2008","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymgme.2017.09.004_bb0075","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.18295\/2075-0528.1676","article-title":"The role of damage-associated molecular patterns (DAMPs) in human diseases: part II: DAMPs as diagnostics, prognostics and therapeutics in clinical medicine","volume":"15","author":"Land","year":"2015","journal-title":"Sultan Qaboos Univ. Med. J."},{"key":"10.1016\/j.ymgme.2017.09.004_bb0080","series-title":"Robbins Basic Pathology","author":"Kumar","year":"2012"},{"key":"10.1016\/j.ymgme.2017.09.004_bb0085","series-title":"Fabry Disease: Perspectives From 5Years of FOS","article-title":"Natural history of Fabry disease","author":"Mehta","year":"2006"},{"key":"10.1016\/j.ymgme.2017.09.004_bb0090","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/cge.12261","article-title":"Intrafamilial phenotypic variability in four families with Anderson-Fabry disease","volume":"86","author":"Rigoldi","year":"2014","journal-title":"Clin. Genet."},{"key":"10.1016\/j.ymgme.2017.09.004_bb0095","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.bbamcr.2008.12.001","article-title":"Lysosomal disorders: from storage to cellular damage","volume":"1793","author":"Ballabio","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ymgme.2017.09.004_bb0100","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymgme.2017.09.004_bb0105","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ymgme.2011.06.007","article-title":"Higher apoptotic state in Fabry disease peripheral blood mononuclear cells: effect of globotriaosylceramide","volume":"104","author":"De Francesco","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2017.09.004_bb0110","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ymgme.2013.02.003","article-title":"Fabry disease peripheral blood immune cells release inflammatory cytokines: role of globotriaosylceramide","volume":"109","author":"De Francesco","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2017.09.004_bb0115","first-page":"1","article-title":"Innate and adaptive immune response in Fabry disease","volume":"22","author":"Mauhin","year":"2015","journal-title":"J. Inherit. Metab. Dis. Rep."},{"key":"10.1016\/j.ymgme.2017.09.004_bb0120","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/1531-8249(200002)47:2<229::AID-ANA13>3.0.CO;2-T","article-title":"Profile of endothelial and leukocyte activation in Fabry patients","volume":"47","author":"DeGraba","year":"2000","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymgme.2017.09.004_bb0125","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ymgme.2008.06.016","article-title":"Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells","volume":"95","author":"Shen","year":"2008","journal-title":"Mol. Genet. Metab."},{"issue":"Suppl. 1","key":"10.1016\/j.ymgme.2017.09.004_bb0130","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1007\/s10545-009-1060-9","article-title":"Leukocyte perturbation associated with Fabry disease","volume":"32","author":"Rozenfeld","year":"2009","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2017.09.004_bb0135","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.bbadis.2011.11.001","article-title":"Globotriaosylceramide is correlated with oxidative stress and inflammation in Fabry patients treated with enzyme replacement therapy","volume":"1822","author":"Biancini","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ymgme.2017.09.004_bb0140","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.mrgentox.2015.04.012","article-title":"DNA damage in Fabry patients: an investigation of oxidative damage and repair","volume":"784\u2013785","author":"Biancini","year":"2015","journal-title":"Mutat. Res. Genet. Toxicol. Environ. Mutagen."},{"key":"10.1016\/j.ymgme.2017.09.004_bb0145","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.cca.2016.07.016","article-title":"Biomolecules damage and redox status abnormalities in Fabry patients before and during enzyme replacement therapy","volume":"461","author":"Biancini","year":"2016","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.ymgme.2017.09.004_bb0150","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s10545-007-0513-2","article-title":"High incidence of autoantibodies in Fabry disease patients","volume":"30","author":"Martinez","year":"2007","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2017.09.004_bb0155","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s00467-006-0176-5","article-title":"IgA nephropathy in two adolescent sisters heterozygous for Fabry disease","volume":"21","author":"Whybra","year":"2006","journal-title":"Pediatr. Nephrol."},{"key":"10.1016\/j.ymgme.2017.09.004_bb0160","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1084\/jem.188.8.1529","article-title":"CD1d-restricted recognition of synthetic glycolipid antigens by human natural killer T cells","volume":"188","author":"Spada","year":"1998","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ymgme.2017.09.004_bb0165","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.coi.2003.11.014","article-title":"New insights into pathways for CD1-mediated antigen presentation","volume":"16","author":"Sugita","year":"2004","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.ymgme.2017.09.004_bb0170","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ymgme.2013.01.018","article-title":"Invariant natural killer T cells are phenotypically and functionally altered in Fabry disease","volume":"108","author":"Pereira","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2017.09.004_bb0175","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1007\/s10753-015-0214-1","article-title":"Elevated endomyocardial biopsy macrophage-related markers in intractable myocardial diseases","volume":"38","author":"Hayashi","year":"2015","journal-title":"Inflammation"},{"key":"10.1016\/j.ymgme.2017.09.004_bb0180","doi-asserted-by":"crossref","first-page":"e20534","DOI":"10.1371\/journal.pone.0020534","article-title":"A distinct urinary biomarker pattern characteristic of female Fabry patients that mirrors response to enzyme replacement therapy","volume":"6","author":"Kistler","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2017.09.004_bb0185","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1039\/c3mb25402j","article-title":"Alteration of proteomic profiles in PBMC isolated from patients with Fabry disease: preliminary findings","volume":"9","author":"Cigna","year":"2013","journal-title":"Mol. BioSyst."},{"key":"10.1016\/j.ymgme.2017.09.004_bb0190","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1651-2227.2008.00654.x","article-title":"Apoptotic abnormalities in differential gene expression in peripheral blood mononuclear cells from children with Fabry disease","volume":"97","author":"Moore","year":"2008","journal-title":"Acta Paediatr."},{"key":"10.1016\/j.ymgme.2017.09.004_bb0195","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1476-9255-9-4","article-title":"Apoptosis inhibition or inflammation: the role of NAIP protein expression in Hodgkin and non-Hodgkin lymphomas compared to non-neoplastic lymph node","volume":"9","author":"Mazrouei","year":"2012","journal-title":"J. Inflamm. (Lond.)"},{"key":"10.1016\/j.ymgme.2017.09.004_bb0200","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nm.3893","article-title":"Inflammasomes: mechanism of action, role in disease, and therapeutics","volume":"21","author":"Guo","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymgme.2017.09.004_bb0205","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1039\/C4MB00707G","article-title":"Early markers of Fabry disease revealed by proteomics","volume":"11","author":"Matafora","year":"2015","journal-title":"Mol. BioSyst."},{"key":"10.1016\/j.ymgme.2017.09.004_bb0210","first-page":"401","article-title":"Expression of genes and their responses to enzyme replacement therapy in a Fabry disease mouse model","volume":"24","author":"Park","year":"2009","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.ymgme.2017.09.004_bb0215","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1146\/annurev-immunol-032414-112227","article-title":"Molecular mechanisms in genetically defined autoinflammatory diseases: disorders of amplified danger signaling","volume":"33","author":"de Jesus","year":"2015","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.ymgme.2017.09.004_bb0220","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1097\/01.ASN.0000121781.89599.16","article-title":"Signaling danger: toll-like receptors and their potential roles in kidney disease","volume":"15","author":"Anders","year":"2004","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2017.09.004_bb0225","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1093\/hmg\/ddv291","article-title":"Lyso-Gb3 activates Notch1 in human podocytes","volume":"24","author":"Sanchez-Ni\u00f1o","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymgme.2017.09.004_bb0230","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1073\/pnas.0912937107","article-title":"Involvement of the Toll-like receptor 4 pathway and use of TNF-alpha antagonists for treatment of the mucopolysaccharidoses","volume":"107","author":"Simonaro","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymgme.2017.09.004_bb0235","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1523\/JNEUROSCI.5282-06.2007","volume":"27","author":"Suzuki","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ymgme.2017.09.004_bb0240","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/ncpneph0806","article-title":"Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults","volume":"4","author":"Ortiz","year":"2008","journal-title":"Nat. Clin. Pract. Nephrol."},{"key":"10.1016\/j.ymgme.2017.09.004_bb0245","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1097\/GIM.0b013e3181bb05bb","article-title":"Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry","volume":"11","author":"Waldek","year":"2009","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2017.09.004_bb0250","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1136\/jmedgenet-2015-103471","article-title":"Antiproteinuric therapy and Fabry nephropathy: factors associated with preserved kidney function during agalsidase-beta therapy","volume":"52","author":"Warnock","year":"2015","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2017.09.004_bb0255","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","article-title":"Agalsidase-beta therapy for advanced Fabry disease: a randomized trial","volume":"146","author":"Banikazemi","year":"2007","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ymgme.2017.09.004_bb0260","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1681\/ASN.2006080816","article-title":"Sustained, long-term renal stabilization after 54months of agalsidase beta therapy in patients with Fabry disease","volume":"18","author":"Germain","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2017.09.004_bb0265","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/00041552-200401000-00005","article-title":"Cellular responses to protein overload: key event in renal disease progression","volume":"13","author":"Zoja","year":"2004","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"10.1016\/j.ymgme.2017.09.004_bb0270","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1093\/ndt\/gfp528","article-title":"Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN)","volume":"25","author":"Fogo","year":"2010","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymgme.2017.09.004_bb0275","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1046\/j.1523-1755.2002.00675.x","article-title":"Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy","volume":"62","author":"Thurberg","year":"2002","journal-title":"Kidney Int."},{"key":"10.1016\/j.ymgme.2017.09.004_bb0280","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.coph.2009.04.008","article-title":"Anti-inflammatory and pro-inflammatory roles of TGF-beta, IL-10, and IL-22 in immunity and autoimmunity","volume":"9","author":"Sanjabi","year":"2009","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.ymgme.2017.09.004_bb0285","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.3892\/ijmm.2012.1139","article-title":"Possible role of transforming growth factor-beta1 and vascular endothelial growth factor in Fabry disease nephropathy","volume":"30","author":"Lee","year":"2012","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.ymgme.2017.09.004_bb0290","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1093\/ndt\/gfq306","article-title":"Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy","volume":"26","author":"Sanchez-Ni\u00f1o","year":"2011","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymgme.2017.09.004_bb0295","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3109\/08923973.2015.1127382","article-title":"TGF-beta: the connecting link between nephropathy and fibrosis","volume":"38","author":"Sutariya","year":"2016","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"10.1016\/j.ymgme.2017.09.004_bb0300","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.cytogfr.2012.08.001","article-title":"MIF, CD74 and other partners in kidney disease: tales of a promiscuous couple","volume":"24","author":"Sanchez-Ni\u00f1o","year":"2013","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.ymgme.2017.09.004_bb0305","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.bbadis.2009.06.004","article-title":"TGF-beta and fibrosis in different organs - molecular pathway imprints","volume":"1792","author":"Pohlers","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ymgme.2017.09.004_bb0310","doi-asserted-by":"crossref","first-page":"e0136442","DOI":"10.1371\/journal.pone.0136442","article-title":"Epithelial-mesenchymal transition in kidney tubular epithelial cells induced by globotriaosylsphingosine and globotriaosylceramide","volume":"10","author":"Jeon","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2017.09.004_bb0315","doi-asserted-by":"crossref","first-page":"e97985","DOI":"10.1371\/journal.pone.0097985","article-title":"TLR4 activation promotes podocyte injury and interstitial fibrosis in diabetic nephropathy","volume":"9","author":"Ma","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2017.09.004_bb0320","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0065-2776(06)91004-9","article-title":"Endogenous TLR ligands and autoimmunity","volume":"91","author":"Wagner","year":"2006","journal-title":"Adv. Immunol."},{"key":"10.1016\/j.ymgme.2017.09.004_bb0325","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1681\/ASN.2007040395","article-title":"TLR4 links podocytes with the innate immune system to mediate glomerular injury","volume":"19","author":"Banas","year":"2008","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2017.09.004_bb0330","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2326409816648169","article-title":"The kidney in Fabry disease: more than mere sphingolipids overload","volume":"4","author":"Trimarchi","year":"2016","journal-title":"J. Inborn Errors Metab. Screen"},{"key":"10.1016\/j.ymgme.2017.09.004_bb0335","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nrneph.2015.215","article-title":"Renal fibrosis in 2015: understanding the mechanisms of kidney fibrosis","volume":"12","author":"Zhou","year":"2016","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.ymgme.2017.09.004_bb0340","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nrneph.2014.114","article-title":"Inflammatory processes in renal fibrosis","volume":"10","author":"Meng","year":"2014","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.ymgme.2017.09.004_bb0345","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1136\/hrt.2010.204586","article-title":"The right ventricle in Fabry disease: natural history and impact of enzyme replacement therapy","volume":"96","author":"Niemann","year":"2010","journal-title":"Heart"},{"key":"10.1016\/j.ymgme.2017.09.004_bb0350","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/j.humpath.2015.07.017","article-title":"Increased oxidative stress contributes to cardiomyocyte dysfunction and death in patients with Fabry disease cardiomyopathy","volume":"46","author":"Chimenti","year":"2015","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.ymgme.2017.09.004_bb0355","series-title":"Fabry Disease: Perspectives From 5 Years of FOS","article-title":"The heart in Fabry disease","author":"Linhart","year":"2006"},{"key":"10.1016\/j.ymgme.2017.09.004_bb0360","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.cjca.2017.04.015","article-title":"Clinical features, diagnosis, and management of Patients with Anderson-Fabry cardiomyopathy","volume":"33","author":"Yogasundaram","year":"2017","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.ymgme.2017.09.004_bb0365","doi-asserted-by":"crossref","first-page":"1221.e1","DOI":"10.1016\/j.cjca.2015.10.033","article-title":"Evaluation of proinflammatory prognostic biomarkers for Fabry cardiomyopathy with enzyme replacement therapy","volume":"32","author":"Chen","year":"2016","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.ymgme.2017.09.004_bb0370","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.carpath.2009.05.003","article-title":"A detailed pathologic examination of heart tissue from three older patients with Anderson-Fabry disease on enzyme replacement therapy","volume":"19","author":"Sheppard","year":"2010","journal-title":"Cardiovasc. Pathol."},{"key":"10.1016\/j.ymgme.2017.09.004_bb0375","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ymgme.2009.10.004","article-title":"Vasculopathy in patients with Fabry disease: current controversies and research directions","volume":"99","author":"Rombach","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2017.09.004_bb0380","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1161\/HYPERTENSIONAHA.112.195685","article-title":"Vascular aspects of Fabry disease in relation to clinical manifestations and elevations in plasma globotriaosylsphingosine","volume":"60","author":"Rombach","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.ymgme.2017.09.004_bb0385","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/sj.jhh.1002101","article-title":"Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade","volume":"21","author":"Dandona","year":"2007","journal-title":"J. Hum. Hypertens."},{"key":"10.1016\/j.ymgme.2017.09.004_bb0390","series-title":"Fabry Disease: Perspectives from 5 Years of FOS","article-title":"Neurological manifestations of Fabry disease","author":"Schiffmann","year":"2006"},{"key":"10.1016\/j.ymgme.2017.09.004_bb0395","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2017.09.004_bb0400","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(08)61589-5","article-title":"Fabry's disease","volume":"372","author":"Zarate","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ymgme.2017.09.004_bb0405","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1212\/01.WNL.0000166000.24321.4F","article-title":"Effect of genetic modifiers on cerebral lesions in Fabry disease","volume":"64","author":"Altarescu","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.ymgme.2017.09.004_bb0410","article-title":"Long time enzyme replacement therapy stabilizes obstructive lung disease and alters peripheral immune cell subsets in Fabry patients","author":"Odler","year":"2016","journal-title":"Clin. Respir. J."},{"key":"10.1016\/j.ymgme.2017.09.004_bb0415","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/jhg.2015.123","article-title":"Unravelling the mechanism of action of enzyme replacement therapy in Fabry disease","volume":"61","author":"Ko","year":"2016","journal-title":"J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2017.09.004_bb0420","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/cge.12613","article-title":"X-chromosome inactivation in female patients with Fabry disease","volume":"89","author":"Echevarria","year":"2016","journal-title":"Clin. Genet."},{"key":"10.1016\/j.ymgme.2017.09.004_bb0425","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ymgme.2017.03.005","article-title":"Genetic epidemiological study doesn't support GLA IVS4+919G>A variant is a significant mutation in Fabry disease","volume":"121","author":"Chiang","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2017.09.004_bb0430","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1093\/ndt\/gfm096","article-title":"Safety and pharmacokinetics of agalsidase alfa in patients with Fabry disease and end-stage renal disease","volume":"22","author":"Pastores","year":"2007","journal-title":"Nephrol. Dial. Transplant."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719217302925?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719217302925?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T18:47:29Z","timestamp":1750877249000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719217302925"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":86,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S1096719217302925"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2017.09.004","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Contribution of inflammatory pathways to Fabry disease pathogenesis","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2017.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}